^
Association details:
| Biomarker: | EGFR T790M + MET positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tabrecta (capmatinib) (c-MET inhibitor) + nazartinib (EGF816) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1284P - MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
Published date:
09/14/2020
Excerpt:
In Ph 2, stage IIIB/IV NSCLC pts...Efficacy and safety are reported for pretreated pts with EGFR TKI resistance, with any T790M/MET (Group 1) and treatment (tx)-naive pts with T790M-, any MET (Group 3)....In MET+ pretreated pts, capmatinib plus nazartinib demonstrated clinically relevant efficacy and confirms the role of selective MET inhibition in this subset of post-EGFR TKI pts. Capmatinib plus nazartinib was well tolerated, with similar safety profile across the groups.
Trial ID:
